RXF Technologies, Inc. – Trademark Portfolio

Entity Type: 03

RXF Technologies, Inc. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include OCALIVA. The owner is based in Royal Oak, MI.

27332 Woodward Avenue, Suite 200

Royal Oak, MI 48067

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark
Serial #86715524
Registered 2015
OCALIVA
OCALIVA
Registered 2015
QIJUVA
QIJUVA
Abandoned 2015
OCALIVA
OCALIVA
Registered 2015
QIJUVA
QIJUVA
Abandoned 2015
QIFEXYR
QIFEXYR
Abandoned 2014
NUFEXYR
NUFEXYR
Abandoned 2014
NUFEXERA
NUFEXERA
Abandoned 2014

Trademark Classifications

RXF Technologies, Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (9 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does RXF Technologies, Inc. have?

RXF Technologies, Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 3 registered, 6 abandoned.

What trademark classes does RXF Technologies, Inc. file in?

RXF Technologies, Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are RXF Technologies, Inc.'s most well-known trademarks?

RXF Technologies, Inc.'s registered trademark portfolio includes well-known marks such as OCALIVA. These are among 3 currently registered trademarks in the portfolio.

What is RXF Technologies, Inc.'s trademark registration success rate?

RXF Technologies, Inc. has a 33% trademark registration rate, with 3 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.